ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

ESMO China Voice | Professor Bin Shao : Comprehensive Genomic Analysis of Advanced HR+/HER2- Breast Cancer Patients Using Liquid Biopsy

HR+/HER2- is the most common subtype of breast cancer, accounting for approximately 65% to 70% of all breast cancer cases. Improving the survival benefits for patients with advanced HR+/HER2- breast cancer has always been a hot topic in this field and a unanimous goal for scholars and experts. Exploring the genomic characteristics of advanced HR+/HER2- breast cancer can enhance our understanding of it, and even identify potential biomarkers that affect its treatment and prognosis. The team led by Professor Li Huiping from the Peking University Cancer Hospital conducted a comprehensive genomic analysis of advanced HR+/HER2- breast cancer patients using liquid biopsy technology. Their research results were included as a poster (abstract number: 496P) at this year's ESMO conference. Oncology Frontier has specially invited Professor Shao Bin to introduce the latest results of this study.
Prof. Jun Ma Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Prof. Jun Ma Highlights ASH Conference, Showcasing Chinese Influence on Global Stage

Local time on December 9th, the eagerly awaited 65th American Society of Hematology (ASH) Annual Meeting officially kicked off in San Diego, USA. The Oncology Insight reporting team delved into the forefront, witnessing the impressive presence of "The Voice of China" on the international stage. ASH is one of the largest and most comprehensive international academic conferences in the field of hematology globally, attracting numerous experts and scholars from around the world each year, including a significant representation from China. On the second day of the conference, we had the privilege of interviewing Professor Jun Ma, a leading figure in the field of hematology in China and the Director of the Harbin Institute of Hematology and Oncology. He shared his insights and highlights of this year's conference. Below is Professor Jun Ma's perspective:
ASH 2023 | West China Team: Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

ASH 2023 | West China Team: Exploration of Blinatumomab and Reduced Dosing of Cyclophosphamide before and after Allogeneic Hematopoietic Stem Cell Transplantation

The 65th American Society of Hematology (ASH) Annual Meeting was held in San Diego, California, from December 9 to 12, 2023. ASH Annual Meeting is the largest and most comprehensive international event covering both basic and clinical research in hematlogy. This year, the Hematology Department at West China Hospital, Sichuan University, presented two oral reports, and we delve into these studies:
Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

Professor Cai-Cun Zhou: KRAS G12D Inhibitor HRS-4642 Shows Encouraging Activity in Late-Stage Solid Tumors with KRAS G12D Mutation

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Tumor Insight team delved into the front lines, capturing international advancements and witnessing China's contributions to the field of oncology on the global stage. Professor Cai-Cun Zhou from Tongji University Affiliated Shanghai Pulmonary Hospital delivered an important oral presentation at this conference (Abstract No: LBA33). In a live interview with "Tumor Insight," Professor Zhou shared insights into the research on the novel KRAS G12D inhibitor HRS-4642 for the treatment of late-stage solid tumor patients with KRAS G12D mutation, as well as thoughts and perspectives on the future direction of drug development. This article summarizes the relevant content for readers.
ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

ESMO Big Shot Interview | Professor Xu Ruihua: Oncology in China Is Thriving, with a Record Number of Selected Papers

The 2023 European Society for Medical Oncology (ESMO) Annual Congress was held in Madrid, Spain from October 20th to 24th. The Oncology Horizon team went deep into the front lines, capturing international advancements and witnessing the progress of cancer research in China on the global stage. Professor Xu Ruihua from Sun Yat-sen University Cancer Center delivered a significant oral presentation at this year's congress. In an interview with "Oncology Horizon," Professor Xu shared highlights from the field of gastrointestinal oncology at ESMO and provided insights into the congress. This article compiles relevant content for our readers.